TSS
AVTX icon

Two Sigma Securities’s Avalo Therapeutics AVTX Stock Holding History

Two Sigma Securities’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-65
Closed -$1.88K – 3014
2023
Q3 		$1.88K Sell
65
-21
-24% -$938 ﹤0.01% 2828
2023
Q2 		$7.29K Buy
+86
New +$57.9K ﹤0.01% 2632

Other funds holding AVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Two Sigma Securities's AVTX Position: Q4 2023 in Review

Two Sigma Securities sold out of Avalo Therapeutics (AVTX) in Q4 2023, closing a stake of 65 shares — an estimated $1.88K sold.

Two Sigma Securities first reported a position in AVTX in Q2 2023 and held it in 2 quarters. The position peaked at $7.29K in Q2 2023. 12 funds tracked by Wall St. Rank hold AVTX as of Q4 2023.

  • Two Sigma Securities reported no remaining Avalo Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Securities sold 65 Avalo Therapeutics shares in Q4 2023, an estimated $1.88K.
  • Two Sigma Securities first reported a position in Avalo Therapeutics in Q2 2023 and held it in 2 quarters.
  • Two Sigma Securities's Avalo Therapeutics position peaked at $7.29K in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2023.

Based on Two Sigma Securities's 13F filing for Q4 2023, filed 14 Feb 2024.